Singapore markets closed
Straits Times Index
3,303.19 +10.26 (+0.31%) S&P 500
5,157.44 +29.65 (+0.58%) Dow
38,831.23 +155.55 (+0.40%) Nasdaq
16,251.50 +95.17 (+0.59%) Bitcoin USD
63,790.16 -204.59 (-0.32%) CMC Crypto 200
1,369.25 +56.62 (+4.31%)
ABT May 2024 110.000 put
OPR - OPR Delayed price. Currency in USD
Add to watchlist
As of 03:09PM EDT. Market open.
| Previous close | 3.9200 |
| Open | 3.9400 |
| Bid | 3.3000 |
| Ask | 5.4500 |
| Strike | 110.00 |
| Expiry date | 2024-05-03 |
| Day's range | 3.9400 - 3.9400 |
| Contract range | N/A |
| Volume | |
| Open interest | 6 |
ZacksIs Trending Stock Abbott Laboratories (ABT) a Buy Now?
Recently, Zacks.com users have been paying close attention to Abbott (ABT). This makes it worthwhile to examine what the stock has in store.
ZacksPBH vs. ABT: Which Stock Is the Better Value Option?
PBH vs. ABT: Which Stock Is the Better Value Option?
PR NewswireAbbott's Breakthrough Dissolving Stent Receives FDA Approval for Arteries Below the Knee
Abbott (NYSE: ABT) today announced that the U.S. Food and Drug Administration (FDA) has approved the Esprit™ BTK Everolimus Eluting Resorbable Scaffold System (Esprit BTK System), a breakthrough innovation for people with chronic limb-threatening ischemia (CLTI) below-the-knee (BTK). The Esprit BTK System is designed to keep arteries open and deliver a drug (Everolimus) to support vessel healing prior to completely dissolving.
© 2024 Yahoo. All rights reserved.